Kanaly Trust’s CorMedix CRMD Stock Holding History

Kanaly Trust’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$4K	Hold	514	–	–	﹤0.01%	692
2016 Q3	$6K	Hold	514	–	–	﹤0.01%	606
2016 Q2	$5K	Hold	514	–	–	﹤0.01%	636
2016 Q1	$7K	Hold	514	–	–	﹤0.01%	597
2015 Q4	$5K	Hold	514	–	–	﹤0.01%	656
2015 Q3	$5K	Buy	+514	New	+$7.93K	﹤0.01%	635

Other funds holding CRMD

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GLRA

Gerald L. Ray & Associates Dallas, Texas $802M AUM 21.01% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Kanaly Trust's CRMD Position: Q4 2016 in Review

Kanaly Trust held its CorMedix (CRMD) position steady in Q4 2016 at 514 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #692.

Kanaly Trust first reported a position in CRMD in Q3 2015 and has held it in 6 quarters since. The position peaked at $7K in Q1 2016. 38 funds tracked by Wall St. Rank hold CRMD as of Q4 2016.

Kanaly Trust held 514 shares of CorMedix worth $4K as of Q4 2016.
Kanaly Trust left its CorMedix share count unchanged in Q4 2016.
CorMedix made up ﹤0.01% of Kanaly Trust's portfolio in Q4 2016, its #692 holding.
Kanaly Trust first reported a position in CorMedix in Q3 2015 and has held it in 6 quarters since.
Kanaly Trust's CorMedix position peaked at $7K in Q1 2016.
38 funds tracked by Wall St. Rank held CorMedix as of Q4 2016.

Based on Kanaly Trust's 13F filing for Q4 2016, filed 23 Jan 2017.